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PBRM1 acts as a p53 lysine-acetylation reader to
suppress renal tumor growth
Weijia Cai 1, Liya Su1, Lili Liao1,2, Zongzhi Z. Liu2, Lauren Langbein 1, Essel Dulaimi3, Joseph R. Testa 3,
Robert G. Uzzo3, Zhijiu Zhong4, Wei Jiang1, Qin Yan 2, Qing Zhang 5,6* & Haifeng Yang1*
p53 acetylation is indispensable for its transcriptional activity and tumor suppressive func-
tion. However, the identity of reader protein(s) for p53 acetylation remains elusive. PBRM1,
the second most highly mutated tumor suppressor gene in kidney cancer, encodes PBRM1.
Here, we identify PBRM1 as a reader for p53 acetylation on lysine 382 (K382Ac) through its
bromodomain 4 (BD4). Notably, mutations on key residues of BD4 disrupt recognition of p53
K382Ac. The mutation in BD4 also reduces p53 binding to promoters of target genes such as
CDKN1A (p21). Consequently, the PBRM1 BD4 mutant fails to fully support p53 transcriptional
activity and is defective as a tumor suppressor. We also ﬁnd that expressions of PBRM1 and
p21 correlate with each other in human kidney cancer samples. Our ﬁndings uncover a tumor
suppressive mechanism of PBRM1 in kidney cancer and provide a mechanistic insight into the
crosstalk between p53 and SWI/SNF complexes.
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T P53, the tumor suppressive gene (TSG) that encodes p53,plays a pivotal role in suppressing tumor growth mainlythrough its transcriptional activity1. Various post-
translational modiﬁcations occur on p53, and acetylation on
eight key lysine residues was found to be critical for modulation
of its transcriptional activity2. p53 acetylation can be divided into
two groups: acetylation on two lysine residues in p53′s DNA-
binding domain (K120 and K164), which directly affects its
binding to DNA2–4 and acetylation on six lysine residues in p53’s
C-terminal domain (CTD) (K370, K372, K373, K381, K382, and
K386), which regulates its transcriptional activity through
interactions with other proteins, also known as acetylation
‘readers’5–11. p53 acetylation ‘writers’ such as histone acetyl-
transferases and ‘erasers’ such as histone deacetylases and sirtuins
are well described1, but the identities and functions of p53 acet-
ylation ‘readers’ remain unclear. CREB-binding protein (CBP)
was the only identiﬁed CTD acetylation ‘reader’ which recognizes
and binds to p53 acetylated at K382 (K382Ac) and enhances p53
transcription9. SET bound to unacetylated CTD and inhibited
p53’s transcriptional activity10. However, CBP and SET fail to
fully account for the biological activity of p53′s acetylated CTD,
suggesting that other reader(s) exists.
In agreement with it being a pivotal TSG, around half of
human tumors harbor mutations in TP53. Interestingly, clear cell
Renal Cell Carcinoma (ccRCC), the most common subtype of
kidney cancer, seems to be an exception: only a small subset of
tumors harbor mutations in TP53 (~3%)12. This suggests the
possibility that p53 tumor suppressor function may be compro-
mised by mutations of other genes in ccRCC tumors. We
investigated whether mutations in the Polybromo-1 gene
(PBRM1) in ccRCC impaired the p53 pathway indirectly. PBRM1
is mutated in approximately 40% of ccRCC tumors13. PBRM1,
also called BAF180, functions as a chromatin-targeting subunit of
a SWI/SNF chromatin remodeler complex and regulates inter-
feron stimulated gene factor 314,15. Its mutation ampliﬁes the
HIF-response and collaborates with Vhl mutation to generate
ccRCC in mouse models16–18. A recent paper reported that the
components of SWI/SNF complexes had an overall 20% mutation
rate in cancer, which is the second most highly mutated entity
next to p53. SWI/SNF mutations are also mutually exclusive with
TP53 mutations in many cancer types19. Certain SWI/SNF
complex components were reported to interact with p53 and were
required for p53 function, especially in senescence20–25. Notably,
PBRM1 was required for p53-mediated replicative senescence in
human primary ﬁbroblasts26. Hence, we investigate whether
PBRM1, through its six acetyl-lysine binding bromodomains
(BDs), functions as a reader of acetylated p53. We ﬁnd that BD4
of PBRM1 is critical for recognition of K382Ac on p53 and this is
critical for PBRM1′s tumor suppressor function.
Results
PBRM1 and p53 binding is enhanced by DNA damage. To test
whether PBRM1 is a potential acetyl-lysine reader of p53, we ﬁrst
examined whether PBRM1 interacts with p53. The immunopre-
cipitation results show Flag-tagged PBRM1 bound to endogenous
p53 in U2OS osteosarcoma cells (Fig. 1a, left) and human
embryonic kidney 293T (HEK293T) cells (Fig. 1a, right). Since
p53 is activated after DNA damage, we induced DNA damage in
p53-null H1299 lung cancer cells co-transfected with PBRM1
and p53 followed by etoposide or bleomycin treatment and found
PBRM1-p53 interactions were enhanced (lane 7 vs. lane 3 or lane
5 on Fig. 1b and lane 9 vs. lane 5 on Fig. 1c). It is important to
note that neither the PBRM1 nor the exogenous p53 levels
changed upon DNA damage (likely because the high rate of
exogenous p53 production exceeds its degradation), suggesting
that the increased interaction may be due to changes in post-
translational modiﬁcations on these proteins. DNA damage did
signiﬁcantly increase the endogenous p53 protein levels in most
cases. In HEK293 cells, p53 pulled down PBRM1, and DNA
damage increased the amount of endogenous PBRM1 pre-
cipitated by similar amount of endogenous p53 (Fig. 1d). In
kidney cancer cell lines ACHN, Caki-1 and Ren-01, increased
endogenous p53 associated with more endogenous PBRM1 after
DNA damage (Supplementary Fig. 1a–c). To conﬁrm the endo-
genous interaction is not due to nonspeciﬁc binding by anti-
bodies, we performed the immunoprecipitation in HCT116 p53
wild-type colorectal carcinoma cells compared with isogenic p53
null cells. The result showed that p53 antibody immunoprecipi-
tated endogenous PBRM1 only when p53 was present (Fig. 1e).
Lysine acetylation on the p53 CTD enhances binding to
PBRM1. To address whether the C-terminus of p53 is important
to bind PBRM1, we constructed a series of p53 C-terminal
truncation mutants (Fig. 2a) and found the afﬁnity of these
constructs to PBRM1 was largely diminished by deletion of the
p53 CTD (Fig. 2b). Since p53’s CTD contains several lysines that
are acetylated upon DNA damage and BDs are putative acetyla-
tion readers, we reasoned that lysine acetylation may signiﬁcantly
boost the PBRM1-p53 interaction. p53 can be acetylated by
acetyltransferases including CBP/p300, TIP60/MOF and PCAF11.
We overexpressed HA-tagged CBP, p300, TIP60 and PCAF to
examine which proteins could enhance the PBRM1-p53 interac-
tion, and only CBP and p300 could do so (Fig. 2c). Considering
the role of CBP as a p53 acetylation reader9, we used p300 to
further conﬁrm the enhanced interaction. Since PBRM1 expres-
sion was also enhanced by p300, we titrated p300 expression and
found p300 indeed signiﬁcantly enhanced their interaction when
PBRM1 and p53 levels were almost equal (Fig. 2d, lanes 5 and 6
vs. lane 4). As expected, p300 greatly increased K382Ac levels on
p53 (Fig. 2d), suggesting that it could be a binding signal for
PBRM1’s BDs. After nicotinamide treatment, which inhibits sir-
tuins and increases p53 acetylation, the interaction between
PBRM1 and p53 was also enhanced (Supplementary Fig. 2a),
suggesting that acetylation on p53 might enhance its interaction
with PBRM1. K382Ac seems to be naturally occurring without
the treatment of DNA damaging agents as it can be detected in
the nucleus of cancer cells in human ccRCC tumors (Supple-
mentary Fig. 2b). Moreover, a p53 6KR mutant, in which lysine
residues 370, 372, 373, 381, 382 and 386 were mutated to argi-
nine, failed to increase binding to PBRM1 in presence of p300 co-
expression, despite similar basal binding to PBRM1 as wild-type
p53 (Fig. 2e). This suggests acetylation on the p53 CTD is critical
for the enhanced interaction between PBRM1 and p53.
To identify the acetylation site(s) on the p53 CTD responsible
for the enhanced PBRM1-p53 interaction, we synthesized
biotinylated p53 C-terminal peptides with or without acetylation
on key lysines and tested their ability to bind PBRM1. The
peptide containing acetylated lysine 382 of p53 displayed
signiﬁcantly higher afﬁnity to endogenous PBRM1 and BRD7, a
protein that complexes with PBRM1 in SWI/SNF, in H1299 cells
than the non-acetylated control peptide (Fig. 2f, lane 8 vs. lane 3).
Similar results were obtained in HEK293T and HCT116 cell
lysates (Supplementary Fig. 2b, c), where H3K14Ac is known to
be bound by BD2 of PBRM127. We also tested the afﬁnity of these
peptides toward exogenous full-length PBRM1 or the PBRM1
BDs (BD1–6). In both cases the p53 peptide with K382Ac showed
higher afﬁnity to PBRM1 than the non-acetylated peptide (Fig. 2g,
lane 7 vs. lane 2), suggesting that the bromodomians alone were
sufﬁcient for the enhanced binding to the p53 K382Ac peptide.
Interestingly, the enhanced interaction seemed to be site-speciﬁc,
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as acetylation on other individual sites did not increase the
afﬁnity to PBRM1 compared with the non-acetylated peptide.
Similarly, in two doubly acetylated peptides K372Ac/K382Ac and
K373Ac/K382Ac, only K372Ac/K382Ac showed higher afﬁnity to
PBRM1 than the non-acetylated peptide and even the K382Ac
peptide (Fig. 2g, lane 9 vs. lanes 7 and 2). Moreover, although the
basal bindings were similar, the p53 K382R mutant did not show
a p300-dependent increase in binding to PBRM1 as did the wild-
type p53 (Fig. 2h). Altogether, these data suggest PBRM1 may
recognize particular p53 acetylation pattern/code(s) containing
K382Ac.
BD4 of PBRM1 recognizes p53 K382Ac. To investigate whether
the BDs of PBRM1 interact with p53, we constructed a series of
PBRM1 N-terminal truncations (Fig. 3a) and found that deletion
up to and including BD4 signiﬁcantly reduced the interaction
between PBRM1 and p53 but not with other SWI/SNF complex
components BRG1, BRD7, and BAF57 (Fig. 3b). Moreover,
PBRM1’s six BDs (BD1–6) without the C-terminal portion lost
the ability to bind other SWI/SNF complex components, as
previously shown16, but still bound p53 as well as full-length
PBRM1 (Fig. 3b). This suggests that PBRM1 can bind p53
independently of other SWI/SNF components.
On PBRM1, only BD2 has been identiﬁed as a reader of histone
3 lysine 14 acetylation (H3K14Ac)27, and it is not known which
BD may be responsible for the recognition of K382Ac on p53.
Only BD4 showed detectable afﬁnity to p53 among the six BDs
(Fig. 3c and Supplementary Fig. 3a). BD4 alone bound p53 CTD
peptides but did not show selective afﬁnity to the K382Ac
peptide, whereas the ﬁve other individual BDs failed to bind the
peptides (Supplementary Fig. 3b). We postulated that adjacent
BD(s) may assist BD4 in recognizing p53 acetylated at K382 since
additional BDs assist BD2 in recognizing H3K14Ac, as reported
in two recent papers28,29. The combination of bromodomains 4
and 5 (BD45) showed enhanced binding to the K382Ac peptide
compared to the non-acetylated control (Fig. 3e). To determine
which BD is critical for recognition of p53 acetylation, we
mutated critical YN residues, previously reported to be required
to form a hydrogen bond with the target acetyl-lysine30,31, to
alanines to disrupt bromodomain 4 (BD4*) and 5 (BD5*)
(Fig. 3d). The BD4* mutation in BD45 abolished the enhanced
binding to the K382Ac peptide whereas the BD5* mutation did
not (Fig. 3e). This suggests that BD4, not BD5, is the critical BD
of PBRM1 for enhanced binding to K382 acetylated p53. In vitro,
a puriﬁed GST-BD2345 protein preferentially bound the K382Ac
peptide (Supplementary Fig. 3d, e) whereas GST-BD2, -BD4,
-BD234 and -BD245 failed to do so (Supplementary Fig. 3c, d).
This suggests additional BDs may help facilitate recognition of
lysine acetylation by BD4. We identiﬁed two BD4 tumor-derived
mutations from cBioPortal32,33 (N601K and E602K, Fig. 3d), and
found that they also abolished the increased afﬁnity to the
K382Ac peptide (Fig. 3f). In full-length PBRM1, as expected, the
BD4* mutation did not affect its afﬁnity to H3K14Ac, a putative
substrate of BD2, but speciﬁcally abolished its recognition of
p53 K382Ac (Fig. 3g). Moreover, the interaction between the
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full-length PBRM1 BD4* mutant and p53 was not enhanced by
p300 co-expression (Fig. 3h, compare lanes 5–8). These data
clearly suggest that BD4 of PBRM1 is critical for recognition of
K382Ac on p53.
PBRM1 loss compromises p53′s transcriptional activity. To
assess PBRM1′s role in p53 function, we knocked out PBRM1 in
H1299 cells and found the induction of putative p53 downstream
target p21 (encoded by CDKN1A) was signiﬁcantly reduced upon
p53 transfection (Fig. 4a, b). A PCR array was performed to
examine the expression of most known p53 downstream targets
in the parental and PBRM1 knockout (KO) H1299 cells after
transfection of p53. The results identiﬁed 23 p53 downstream
targets that were signiﬁcantly altered by PBRM1 loss (Supple-
mentary Table 1), and eight of them were further validated by
p53 protein
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real-time PCR experiments (Fig. 4c). Similar results were
obtained in HCT116 PBRM1 knockout cells using etoposide to
activate endogenous p53 (Supplementary Fig. 4a, b), whereas the
spectrum of altered p53 targets was different from those in H1299
cells. Restoration of PBRM1 expression in two different KO
clones excluded the possibilities of off-target and clonal effects,
conﬁrming PBRM1 indeed facilitated p53 transcription of select
targets (Fig. 4d, e, Supplementary Fig. 4c, d). Moreover, with
chromatin immunoprecipitation (ChIP) followed by qPCR, we
found p53 expression enhanced the binding of PBRM1 to both
the response element 1 (RE1) region and transcriptional start site
(TSS) of the CDKN1A gene. Consequently, PBRM1 restoration
enhanced p53 binding to the RE1 region but not the TSS of
CDKN1A (Fig. 4f). To examine whether recognition of K382Ac
by PBRM1 is critical to PBRM1′s role in facilitating p53 tran-
scription, we restored expression of wild-type PBRM1 and the
BD4* mutant in H1299 PBRM1 KO cells (Supplementary Fig. 4e).
Only wild-type PBRM1 restored the expression of p21 driven by
p53 while the BD4* mutant did not (Fig. 4g).
PBRM1 regulates the p53 signaling pathway in ccRCC cells.
Since PBRM1 is frequently mutated in kidney cancer, we inves-
tigated the effects of PBRM1 depletion on the p53 signaling
pathway in several kidney cancer cell lines. Knockdown of
PBRM1 by short hairpin RNAs (shRNAs) signiﬁcantly reduced
p21 induction, and MDM2 induction in most cases, by p53 upon
DNA damage in kidney cancer cell lines ACHN (Fig. 5a and
Supplementary Fig. 5a), Caki-1 (Fig. 5b), and Ren-01 (Supple-
mentary Fig. 5b), all of which express both wild-type PBRM1 and
p53. Conversely, transient exogenous expression of PBRM1 dri-
ven by doxycycline induction (Supplementary Fig. 5c) or tran-
sient transfection (Fig. 5c) induced p21 expression in RCC4, a
p53-wild type and PBRM1-null kidney cancer cell line. To
exclude the possible effects of DNA damage activating other
signaling pathways, we used the MDM2 inhibitor Nutlin-3a to
selectively accumulate and activate p53. We found that p21
induction by p53 was also reduced by PBRM1 knockdown in
ACHN cells (Fig. 5d and Supplementary Fig. 5d). Moreover, over-
expressed PBRM1 failed to induce p21 or MDM2 in the absence
of p53 in RCC4 cells (Fig. 5c). Our data strongly suggest that
PBRM1 is required for full induction of p21 and possibly MDM2
by activated p53 in kidney cancer cells.
In agreement with the results in H1299 PBRM1 KO cells, in
RCC4 cells, the PBRM1 BD4* mutant failed to enhance p21
expression after p53 activation, either by DNA damage (Fig. 5e)
or Nutlin-3a treatment (Supplementary Fig. 5e), whereas wild-
type PBRM1 did. Similarly, the N601K and E602K PBRM1
mutants also failed to enhance p21 expression after DNA damage
(Fig. 5f). Interestingly, PUMA expression was greatly enhanced
by wild-type PBRM1 but not the mutants, while MDM2
expression was impacted to a lesser extent (Fig. 5f). We further
investigated several p53 downstream target genes in RCC4 cells,
and found their expression was up-regulated by restoration of
PBRM1 but not PBRM1 BD4* (Fig. 5g). ChIP experiments also
showed that p53 binding to the RE1 region on the CDKN1A
promoter was signiﬁcantly enhanced by wild-type but not BD4*
mutant PBRM1, whereas p53 binding to the TSS region on
CDKN1A was weak and showed no signiﬁcant change after
PBRM1 expression in RCC4 cells (Fig. 5h). Since p21 is a CDK
inhibitor and its activation leads to G1/S cell cycle arrest, we
analyzed whether reduced p21 induction after DNA damage in
PBRM1-depleted cells affected cell cycle progression in kidney
cancer cells. In ACHN cells, PBRM1 knockdown by two different
shRNAs signiﬁcantly decreased the proportion of G1 phase cells
and increased the proportion of S phase cells after DNA damage
(Fig. 5i, j, and Supplementary Fig. 5i), similar to p53 knockdown
or p21 knockdown (Supplementary Fig. 5g–i). This is consistent
with each having a defect in G1/S cell cycle arrest and suggests
that they share the same pathway to regulate cell cycle
progression.
Regulation of p53 is essential to PBRM1’s TSG function. Next,
we sought to determine whether disruption of PBRM1 recogni-
tion of acetylated p53 is critical to PBRM1’s tumor suppressive
function in vivo. We focused on Ren-01 cells which form tumors
rapidly in nude mice. We restored wild-type or BD4* mutant
PBRM1 expression in Ren-01 PBRM1 KO cells and found the
expression of p53 downstream targets was rescued by wild-type
but not BD4* mutant PBRM1 after DNA damage (Fig. 6a). To
test our hypothesis further, we expressed the same genes in a
PBRM1-null ccRCC cell line SLR24 and performed the same
experiment described in Fig. 6a. After DNA damage, the
expression of p21, PUMA, and MDM2 were signiﬁcantly induced
by wild-type but not BD4* mutant PBRM1 or GFP in SLR24 cells
(Fig. 6b). Thus BD4 mutation on PBRM1 abolishes its ability to
assist p53 to induce a subset of its downstream targets.
In a nude mouse xenograft model, restoration of wild-type
PBRM1 in Ren-01 PBRM1 KO cells suppressed tumor growth
when compared with cells expressing either GFP or the BD4*
PBRM1 mutant (Fig. 6b, c, e, f). This suggests that PBRM1
inhibits kidney tumor growth and recognition of acetylated p53 is
essential to this inhibition. Similar to our in vitro results, p21
expression was also signiﬁcantly increased in tumors expressing
wild-type PBRM1 but not the BD4* mutant (Fig. 6d, g and
Supplementary Fig. 6a). To determine the role of the p53 pathway
in tumors generated by Ren-01 cells, we knocked down the
Fig. 2 Acetylation on K382 of p53 promotes PBRM1 binding. a Schematic depiction of the functional domains of p53 and truncated constructs. FL
full-length, TAD transactivation domain, PRD proline-rich domain, DBD DNA-binding domain, TD tetramerization domain, CTD C-terminal domain.
b HEK293T cells were transfected with vectors, Flag-PBRM1, Myc-p53 and Myc-p53 truncated constructs. After immunoprecipitation with Flag-M2 beads,
the inputs and eluates were analyzed by immunoblots. c Vectors, Flag-PBRM1, Myc-p53 and HA-Tip60, HA-PCAF, HA-CBP or HA-p300 were transfected
into HEK293T cells as indicated. Lysates were used for anti-Flag immunoprecipitation and 3X Flag peptide elution. The inputs and eluates were analyzed by
immunoblots. d HEK293T cells were transfected with Flag-PBRM1, Myc-p53 and HA-p300. The amount of HA-p300 was titrated as indicated. Lysates
were used in immunoprecipitations with Flag-M2 beads, and inputs and eluates were analyzed by immunoblots. e Vectors, Flag-PBRM1, HA-p300 and
Myc-p53 (WT) or Myc-p53 6KR mutant were transfected into HEK293T cells as indicated. Lysates were used for anti-Flag immunoprecipitation and 3X
Flag peptide elution. Inputs and eluates were examined by immunoblots. 6KR: lysines mutated to arginines on p53 at K370, K372, K373, K381, K382, and
K386. f, g Biotinylated p53 peptides with lysine acetylation at the indicated sites were incubated with lysates from H1299 cells (f) or H1299 cells
transfected with full-length PBRM1 or the PBRM1 bromodomains (Flag-PBRM1 FL or Flag-PBRM1-BD1–6, respectively, g). The peptides were pulled down
with streptavidin beads and the associated proteins were analyzed by immunoblots. 6KAc: lysines acetylated on p53 at K370, K372, K373, K381, K382, and
K386. h Vectors, Flag-PBRM1, HA-p300 and Myc-p53 (WT) or Myc-p53 K382R mutant were transfected into HEK293T cells as indicated. Lysates were
used for anti-Flag immunoprecipitation and 3X Flag peptide elution. Inputs and eluates were examined by immunoblots. Source data are provided as a
Source Data ﬁle.
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expression of p53 with shRNA (Supplementary Fig. 6b) and
examined tumor growth in nude mice. Knockdown of p53 in
Ren-01 cells signiﬁcantly accelerated tumor growth (Supplemen-
tary Fig. 6c, d). This suggests that the p53 signaling pathway is
tumor suppressive in Ren-01 cells. Taken together, the role of
PBRM1 in suppressing tumors generated by Ren-01 cells was
likely partially mediated by BD4 recognition of acetylated p53.
PBRM1 loss is associated with p21 loss in human ccRCC
tumors. To conﬁrm whether PBRM1 indeed regulates p53
function in human kidney tumors, we investigated the relation-
ship between PBRM1 and p21 expression by immunohis-
tochemistry (IHC) in human kidney tumor samples with a
ccRCC tissue microarray (Fig. 7a). Across all tumor samples,
statistical analysis showed a signiﬁcant positive correlation
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between PBRM1 loss and p21 loss (p= 0.042) (Fig. 7b and
Supplementary Fig. 7). When the comparison was performed
within each grade, grades 1 and 2 showed highly signiﬁcant
positive correlations between these losses (p= 0.00077 and p=
0.0093, respectively), while grade 3 did not show any and grade
4 showed a weak but signiﬁcant correlation (p= 0.044) (Fig. 7b
and Supplementary Fig. 7). When the comparison was performed
within each stage, only stage 1 tumors showed a highly signiﬁcant
correlation between PBRM1 and p21 losses (p= 0.00074) while
the other stages did not display signiﬁcant correlations (Fig. 7b
and Supplementary Fig. 7). This is likely caused by many genetic
and epigenetic changes that occur at higher grades or tumor
stages that disrupt the correlation between PBRM1 and p21
expression. This analysis suggests that the link between PBRM1
and p21 observed in cell lines is conserved in human tumor
samples.
Discussion
In this report we found that PBRM1 and p53 physically associate.
K382 acetylation on p53, which may be modiﬁed by p300 and
CBP after DNA damage, acts as a binding signal for the BDs of
PBRM1. The backbone of p53 peptide might already bind
PBRM1, and K382Ac enhances this interaction. We identiﬁed
BD4 of PBRM1 as the cognate binding partner of K382Ac on p53
(Fig. 7c). Suppression of PBRM1 reduces the induction of many
p53 transcriptional targets, and the BD4* PBRM1 mutant that
fails to recognize K382Ac on p53 was defective in tumor sup-
pression and regulation of p53 targets (Figs. 4–6). Importantly,
the link between PBRM1 and p21 was preserved in human tumor
samples (Fig. 7). Thus we hypothesize that DNA damage
increases p53 abundance and the K382Ac level, which not only
dissociates SET from p53 to relieve the suppression of p53
transcriptional activity, but it also provides a binding signal to
PBRM1 for enhanced transcription. PBRM1 binds to both
H3K14Ac and K382Ac on p53, and these interactions may retain
p53 much longer at its target promoters to promote full tran-
scriptional activation of its targets (Fig. 7c).
p53 has been reported to interact with many SWI/SNF com-
plex components, including SNF522, BRG123, BAF60a34, BRD720,
and ARID1A21. Here we report that PBRM1 also physically
interacts with p53. It was not previously known whether PBRM1
binds to p53 indirectly via other SWI/SNF subunits. We found
that the PBRM1 BDs alone (BD1–6) failed to bind other SWI/
SNF complex components yet still retained the ability to bind p53
(Fig. 3b). In agreement with this ﬁnding, Flag-BD4 alone bound
p53 (Fig. 3c and Supplementary Fig. 3a) and puriﬁed GST-
BD2345 directly bound the p53 CTD peptide (Supplementary
Fig. 3d, e). This shows the interaction between PBRM1 and p53 is
direct and not mediated by other SWI/SNF complex components.
Although acetylation is indispensable for p53′s transcriptional
function and SWI/SNF complexes function as transcriptional co-
factors, no acetylation-dependent interaction has been reported
between p53 and SWI/SNF complexes. In this study, we report
that acetylation on p53 lysine 382 enhanced the interaction
between PBRM1 and p53 via recognition by PBRM1 BD4. A
previous report showed that the BDs of PBRM1 did not bind to a
p53 K382Ac peptide27. The difference is likely due to the length
of the peptides used. In our experiments, the p53 peptide used
was much longer than theirs (368–393, 26 residues vs. 375–388,
14 residues, respectively) and hence may provide higher afﬁnity
due to a greater potential interaction surface. Nevertheless, two
shorter peptides lacking K370, K372 and K373 (374–393, 20
residues) failed to interact with PBRM1 (Fig. 2f, lane 12 vs. lane 3
and Fig. 2g, lane 12 vs. lane 2). This suggests that those amino
acid residues (368–373), though approximately 10 residues away
from the recognition site (K382Ac), were still critical for PBRM1
binding. Since screening analyses between BDs and acetylated
substrates have generally used peptides of around 15 residues,
they could potentially miss some important discoveries. Two
recent papers28,29 have shown cooperation between BDs of
PBRM1 in recognition of H3K14Ac. The same may be true in this
instance, that other BD(s) collaborates with BD4 to generate
stable recognition of p53 K382Ac (Fig. 3 and Supplementary
Fig. 3). Since the structure of the binding between short peptides
and single BDs is well analyzed31,35, the structural insight gained
from the enhanced afﬁnity between longer peptides and multiple
BDs will be very intriguing. Interestingly, the K382Q mutation on
p53 failed to mimic K382Ac to enhance binding to PBRM1
(Supplementary Fig. 2e, f). We conclude that although the K382Q
mutation abolishes the positive charge of K382, it failed to fully
recapitulate the characteristics of acetylated K382 on p53.
Similar to histone tails, the p53 CTD is enriched in many types
of post-translational modiﬁcations36. Hence the ‘histone code’
hypothesis37, in which histone modiﬁcations recruit other pro-
teins by speciﬁc recognition, likely applies to p53 as well. An
interesting ﬁnding here was that K372Ac/K382Ac double acet-
ylation signiﬁcantly enhanced the interaction between PBRM1
and p53 whereas K373Ac/K382Ac did not enhance, and possibly
even reduced, the interaction. 6KAc, in which all 6 lysine residues
in the p53 CTD were acetylated, diminished the interaction
compared to K382Ac (Fig. 2f, g). This suggests that only certain
pattern(s) of acetylation can enhance p53 recognition by PBRM1.
This hypothesis is logical since recognition by a reader protein
should be relatively selective, considering the complexity of post-
translational modiﬁcations. Notably, we must exercise caution in
hypothesizing that all acetylation on the p53 CTD exert similar
functions, since peptides with individual acetylation or combined
six acetylation exhibit distinct binding to PBRM1. Consistently, a
proteomic screen based on p53 CTD without acetylation or with
6KAc identiﬁed SET bound to unacetylated p53 CTD but failed to
ﬁnd any protein bound to CTD with 6KAc10. This pattern-
speciﬁc recognition may contribute to ﬁne-tuning p53 tran-
scriptional activity since PBRM1 loss decreased expression of only
Fig. 3 Bromodomain 4 of PBRM1 is required for recognition of acetylated K382 on p53. a Schematic depiction of the functional domains of PBRM1 and
truncated constructs. WT: wild-type, BAH: bromo-adjacent homology domain, HMG: high-mobility group domain. b, c HEK293T cells were transfected
with vectors, Flag-WT PBRM1 and Flag-PBRM1 truncated constructs (b), and each individual or all the PBRM1 bromodomains (BD1–6, c). After
immunoprecipitation with Flag-M2 beads, the inputs and eluates were analyzed by immunoblots. d Schematic of key amino acid residues of binding
pockets in PBRM1 bromodomains 4 and 5. The critical YN residues are underlined and mutations are red. e–g H1299 PBRM1 KO cells were transfected with
Flag-PBRM1 bromodomains 4 and 5 (Flag-BD45) containing mutations (BD4* or BD5*) that abolish acetyl-lysine recognition in each domain (e), Flag-
BD45 containing tumor-derived mutations (f) or full-length PBRM1 containing the BD4* mutation (g). Lysates were incubated with biotinylated p53
peptides with lysine acetylation at the indicated sites. The peptides were pulled down with streptavidin beads and the associated proteins were
immunoblotted. h Vectors, Myc-p53, HA-p300, and Flag-PBRM1 with or without the BD4* mutation were transfected into HEK293T PBRM1 knockout cells.
The lysates were subjected to anti-Flag immunoprecipitation and 3X Flag peptide elution. Inputs and eluates were analyzed in immunoblots. Source data
are provided as a Source Data ﬁle.
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a subset of p53 target genes. In future studies, we will investigate
whether different combinations of post-translational modiﬁca-
tions, such as acetylation and methylation, interfere with PBRM1′
s recognition of K382Ac.
The transcriptional activity of p53 is compromised by PBRM1
loss. Mechanistically, we found p53 binding to the CDKN1A
promoter (RE1 region) was enhanced by PBRM1 (Fig. 4f and
Fig. 5h). p53 activation also recruited PBRM1 binding to both the
promoter and TSS of CDKN1A (Figs. 4f and 5h). Unexpectedly,
the PBRM1 BD4* mutant, which failed to recognize p53 K382Ac
but recognized H3K14Ac (Fig. 3g), bound the CDKN1A gene
as well as wild-type PBRM1 (Fig. 5h). Moreover, there was
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comparable PBRM1 binding to the RE1 and TSS whereas p53
binding to RE1 was signiﬁcantly higher than to the TSS (Figs. 4f
and 5h). This suggests PBRM1 was not recruited to the CDKN1A
gene via p53. p53 has been reported to recruit acetyltransferases
such as p300 to acetylate histones and facilitate transcription38.
Now, it seems likely that p53 may trigger histone acetylation,
which recruits PBRM1 via recognition by its BDs. Nevertheless,
the acetylation-dependent interaction between PBRM1 and p53 is
critical for increased p53 binding at the CDKN1A promoter since
the BD4* mutant failed to enhance p53 binding to RE1 (Figs. 5h
and 7c).
Our in vitro and in vivo results, including kidney tumor patient
samples, showed loss of PBRM1 in ccRCC dampened p53 func-
tion and especially p21 expression, which is key for cell cycle
arrest and senescence. This is also consistent with previous
reports showing that PBRM1 knockout in mouse kidneys permits
continued cell proliferation through inhibition of replication
stress39. Replication stress is frequently bypassed by altered p53
pathway in other types of cancers. Lee et al. found PBRM1
deﬁciency induced p21 expression and consequent senescence in
mouse hematopoietic stem cells40. This may be attributed to the
tissue-speciﬁcity of PBRM1 function and may explain why most
PBRM1 mutations are found in renal cancer. Gao et al. found that
knockdown of PBRM1 reduced p21 levels in approximately half
of their tested shRNAs, but they did not draw a clear conclu-
sion16. In our experiments, several techniques including knock-
down, knockout, overexpression and restored expression of
PBRM1 conﬁrmed that PBRM1 regulates p21 expression, and this
effect is much more pronounced after p53 activation. The PBRM1
BD4* mutant, which is highly speciﬁc in its inability to support
the p53 pathway but being able to recognize H3K14Ac, com-
promised the tumor suppressive function of PBRM1 (Fig. 6e, f).
We recently discovered that ISGF3 regulation by PBRM1 is one of
its important tumor suppressor functions in ccRCC15, and our
evidence here suggest that supporting p53 pathway is another
important tumor suppressor function of PBRM1. p21 in combi-
nation with other p53 targets may channel this tumor suppressor
function. In ccRCC, p53 mutations are rare probably because
frequent PBRM1 mutations already partially disable p53 function,
reducing the selection pressure for mutant p53. Since PBRM1
deﬁciency only compromise, not abolish, p53 function on a
subset of p53 targets, it is unlikely to recapitulate all the attributes
of p53 deﬁciency such as high grade and aggressiveness. However,
a partially disabled p53 pathway may still be important for ccRCC
tumorigenesis and/or tumor growth, and this could have ther-
apeutic implications for modulating the p53 pathway to treat
ccRCC patients. In summary, our ﬁndings identiﬁed PBRM1 as a
functional p53 acetylation reader, elucidated the role of the
PBRM1-p53 axis on renal tumor growth, and provided insights
on the crosstalk between SWI/SNF complexes and the p53
pathway.
Methods
Chemicals, reagents, and antibodies. Etoposide (S1225), bleomycin (9041–93–4)
and trichostatin A (TSA, S1045) were purchased from Selleck Chemical. Nutlin-3a
(18585) was purchased from Cayman Chemical. Propidium iodide (PI, P3566) was
purchased from Life Technologies. RNaseA (EN0531), Pierce Protease Inhibitor
Tablets (A32963) and Pierce Phosphatase Inhibitor Mini Tablets (A32957) were
purchased from Thermo Scientiﬁc. Puromycin (P-7255), G418 (A1720), Doxycy-
cline (D9891), and Nicotinamide (NAM, 72340) were purchased from
Millipore Sigma.
Antibodies for vinculin (sc-73614), actin (sc-8432), p53 (FL-393, sc-6243 and
DO-1, sc-126) and p21 (sc-6246) were purchased from Santa Cruz Biotechnology.
Antibodies for GST (#2625), p21 (#2947), PUMA (#12450) and Myc (#2040) were
purchased from Cell Signaling Technology. Anti-PBRM1 (A301–591A), -BRD7
(A302–304A) and -BAF57 antibodies (A300–810A) were purchased from Bethyl
Laboratories. Antibodies for Flag (M2, F3165), MDM2 (OP145) and γH2Ax
(05–636) were purchased from Millipore Sigma. Anti-HA antibody (901514)
was purchased from Biolegend. Anti-p53 K382Ac antibody (GTX62061) was
purchased from GeneTex. For western blotting, except for vinculin (sc-73614)
which was used 1:2000 dilution, all other Santa Cruz Biotech antibodies were used
at 1:200 dilution. All the other antibodies from different companies were used
at 1:1,000 dilution for western blot, except for anti-Flag antibody was used at
0.5 μg/ml. All the original blots used for ﬁgures were included in the PBRM1-p53-
Source Data ﬁle.
Plasmids. The Flag-PBRM1 plasmid was constructed by cloning PBRM1 cDNA
into p3XFlag-CMV10 (Sigma-Aldrich). The Myc-p53 plasmid was constructed by
cloning p53 cDNA into pcDNA3-Myc. The GST-PBRM1 constructs were gener-
ated by subcloning the BDs into the pGST parallel expression vector41.
pCI-Flag-PCAF originated from Nakatani lab (Addgene plasmid #8941)42.
pCMVβ-p300-Myc and pcDNA3β-Flag-CBP-HA were from Tso-Pang Yao’s alb
(Addgene plasmid #32908)43. HA-PCAF, -CBP, and -p300 were generated by
subcloning into a pcDNA3-HA vector. HA-Tip60 plasmid was constructed by
cloning the cDNA into a pcDNA3-HA vector.
Lentiviral Flag-PBRM1 and mutants were generated by subcloning PBRM1 into
a pLNCX-GFP lentiviral vector (a gift from Dr. Wei Xu)44. Mutations in PBRM1
and p53 were generated using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene) according to the manufacturer’s instructions.
Doxycycline-inducible PBRM1 was constructed by subcloning PBRM1 into the
pTetOne vector (Clontech). pLKO.1 lentiviral shRNAs against PBRM1 (#1:
TRCN0000015994, #2: TRCN0000235890), p53 (TRCN0000003755) and p21(#1:
TRCN0000287021, #2: TRCN0000294421) were purchased from Sigma-Aldrich.
pLKO.1 scramble (SCR) shRNA was from David Sabatini’s lab (Addgene plasmid
#1864)45.
For p53 knockout, p53 Double Nickase Plasmid (h) (sc-416469-NIC) was
purchased from Santa Cruz Biotechnology. For PBRM1 knockout, sgRNA primers
(PBRM1-sg2A-F: CACCGTCATCCTTATAGTCTCGGA, PBRM1-sg2A-R: AAA
CTCCGAGACTATAAGGATGAC, PBRM1-sg2B-F: CACCGCTCTGTGAGCTCT
TCATTA, PBRM1-sg2B-R: AAACTAATGAAGAGCTCACAGAGC, PBRM1-
sg7A-F: CACCGGCGAGGAGATCTATATCTT, PBRM1-sg7A-R: AAACAAGAT
ATAGATCTCCTCGCC, PBRM1-sg7B-F: CACCGCCAAAACTTATAATGAG
CC, PBRM1-sg7B-R: AAACGGCTCATTATAAGTTTTGGC, PBRM1-sg20A-F:
CACCGTGGCAACCTGGTTCACCAT, PBRM1-sg20A-R: AAACATGGTGAAC
CAGGTTGCCAC, PBRM1-sg20B-F: CACCGGCTCCATTACAATGACATG and
PBRM1-sg20B-R: AAACCATGTCATTGTAATGGAGCC) were designed using
Optimized Crispr Design (crispr.mit.edu) and cloned into pX335-U6-Chimeric_
BB-CBh-hSpCas9n(D10A)46. All constructs were conﬁrmed by sequencing.
Cell culture and generation of stable cell lines. HEK293, HEK293T, ACHN,
RCC4, Ren-01, SLR24, and NCI-H1299 (H1299) cells were maintained in DMEM
supplemented with 10% FBS. U-2 OS (U2OS), Caki-1, HCT116, and HCT116
p53−/− cells were maintained in McCoy’s 5A supplemented with 10% FBS. All
cells were maintained in incubators with 5% CO2 at 37 °C. HEK293, Caki-1, and
ACHN cells were obtained from ATCC. SLR24 cell line was obtained from Dr.
William Kaelin’s lab at Dana-Farber Cancer Institute.
To establish stable clones with knockdown or restoration of speciﬁc proteins,
cell lines were infected with lentivirus containing the indicated pLKO.1 shRNA
constructs or pLNCX constructs followed by selection with puromycin (2 μg/ml)
for 1 week or G418 (1 mg/ml) for 2 weeks, respectively.
To establish clones with knockout of PBRM1 or p53 or inducible expression of
PBRM1, cell lines were transfected with pX335 constructs plus a linear puromycin
Fig. 4 PBRM1 is required for full p53 transcriptional activity on a subset of its targets. a p53 was transfected into H1299 parental cells and ﬁve PBRM1
knockout clones, and lysates were immunoblotted. b H1299 parental and PBRM1-KO#1 cells were transfected with increasing amounts of p53 and lysates
were immunoblotted. c H1299 parental and PBRM1-KO#1 were transfected with vector or p53, and RNA was extracted and reverse-transcribed. After PCR
array, signiﬁcantly altered p53 target genes were further validated by qPCR. The expression of signiﬁcantly altered genes is shown as mean ± SEM. p-values
were calculated using the paired two-tailed Student’s t-test. d–f Increasing amounts of p53 were transfected into H1299 PBRM1-KO#1 with or without Flag-
PBRM1 re-expression and lysates were analyzed by immunoblots. Cells with comparable p53 expression were harvested for RT-qPCR (e) or ChIP followed
by qPCR (f). Data are shown as mean ± SEM. g H1299 PBRM1-KO#1 cells stably expressing GFP, wild-type or BD4* mutant PBRM1 were transfected with
increasing amounts of p53. Lysates were analyzed by immunoblots. Source data are provided as a Source Data ﬁle.
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marker (631626, Clontech), p53 Double Nickase Plasmid (h) (sc-416469-NIC,
Santa Cruz Biotechnology), or pTetOne construct plus linear puromycin marker
using Lipofectamine™ 2000 (11668019, Thermo Scientiﬁc) or X-tremeGENE™ HP
DNA Transfection Reagent (6366546001, Sigma-Aldrich). After 24 h, cells were
selected with puromycin (2 μg/ml) for 3 days. Surviving cells were diluted and
transferred into 15 cm dishes. After 7–10 days, single colonies were isolated. After
1–2 weeks, cells were harvested for immunoblot analysis to examine the expression
of speciﬁc proteins. For inducible PBRM1 expression, RCC4 cells were treated with
1 μg/ml doxycycline for the indicated times prior to harvest.
Immunoblot and immunoprecipitation. After washing with ice-cold PBS, cells
were scraped on ice and centrifuged at 10,000 × g for 1 min at 4 °C. For immunoblot
analysis, cell pellets were lysed in 1% SDS containing a protease inhibitor cocktail
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followed by sonication with a FB50 sonic dismembrator (Fisher Scientiﬁc) at 20%
amplitude for 15 s twice. After centrifuging for 10min at 14,000 × g, the super-
natants were combined with 5X SDS loading buffer (5% mercaptoethanol, 0.05%
Bromophenol blue, 30% glycerol, 10% SDS, 250mM Tris-HCl (pH 6.8)), boiled for
5 min and used in SDS-PAGE. After standard western blot procedures, the blots
were developed using the ImageQuant LAS 4000 (GE healthcare Life Sciences) or
ChemiDoc MP Imaging System (Bio-rad) with HyGLO™ Chemiluminescent HRP
Detection Reagent (E2500, Denville Scientiﬁc) or Immobilon™ Western Chemilu-
minescent HRP Substrate (WBKLS0500, Millipore).
For anti-Flag immunoprecipitation, cell pellets harvested from one 10 cm
culture dish were resuspended in 500 µl hypotonic buffer (10 mM Tris-HCl, pH
8.0, 1.5 mM MgCl2, 10 mM KCl) with protease and phosphatase inhibitors, 2 μM
TSA and 10 mM NAM, and samples were incubated on ice for 15 min. Twenty-ﬁve
microliters of Triton X-100 was added and samples were vortexed for 10 s. After
centrifuging for 30 s at 14,000 × g, supernatants were removed and pellets were
resuspended in 100 µl hypertonic buffer (20 mM Tris-HCl pH 8.0, 420 mM KCl,
1.5 mM MgCl2, 20% (v/v) glycerol) with protease and phosphatase inhibitors, 2 μM
TSA and 10 mM NAM and vortexed for 10 s. Pellets were incubated on ice for
40 min and vortexed for 15 s every 10 min. After centrifuging for 10 min at
14,000 × g, supernatants were collected and diluted with 300 µl EBC buffer (50 mM
Tris-HCl (pH 7.5), 120 mM NaCl, 0.5% NP-40) with protease and phosphatase
inhibitors, 2 μM TSA and 10 mM NAM. After centrifuging for 10 min at 14,000 ×
g, supernatants were incubated with anti-Flag M2 afﬁnity gel (A2220, Sigma-
Aldrich), for 2 h at 4 °C. Beads were washed four times with EBC buffer and eluted
with 3X Flag peptide (F4799, Sigma-Aldrich) overnight at 4 °C. The input and
Flag-elution were analyzed by SDS-PAGE and immunoblot.
For endogenous p53 immunoprecipitations, cell pellets were lysed in EBC
buffer with protease and phosphatase inhibitors, 2 μM TSA and 10 mM NAM.
Lysates (approximately 2 mg of total protein) were incubated with 2 μg p53
antibody (DO-1) overnight at 4 °C followed by incubation with protein A/G plus
Sepharose (sc-2003, Santa Cruz Biotechnology) for 2 h. Beads were washed with
EBC buffer four times, mixed with 1X SDS loading buffer (1% mercaptoethanol,
0.01% Bromophenol blue, 6% Glycerol, 2% SDS, 50 mM Tris-Cl (pH 6.8)) and
analyzed by SDS-PAGE and immunoblot.
Peptide pull-down assay. Biotinylated peptides with or without acetylated lysine
were synthesized by Anaspec (Fremont, California). The peptides contained resi-
dues 1–21 of histone H3 (ARTKQTARKSTGGKAPRKQLT), residues 368–393 of
p53 (HLKSKKGQSTSRHKKLMFKTEGPDSD) or residues 374–393 of p53
(GQSTSRHKKLMFKTEGPDSD). Cells were lysed in EBC buffer with protease and
phosphatase inhibitors, 2 μM TSA and 10 mM NAM. Lysates were incubated with
peptides for 1 h at 4 °C. Streptavidin beads (20347, Thermo Scientiﬁc) were added
for further 1 h incubation. After washing four times with EBC buffer, the bound
proteins were boiled with 1X SDS loading buffer and examined by immunoblots.
Recombinant protein puriﬁcation. pGST parallel expression plasmids with
PBRM1 BDs were individually expressed in E. coli strain BL21. The expression of
the protein was induced by 0.1 mM isopropyl-β-d-thiogalactoside (IPTG, I6758,
Millipore Sigma) for 20 h at 18 °C. The GST-tagged proteins were puriﬁed with
glutathione-Sepharose 4B (GE Healthcare, Catalog #17–5130–01) according to the
manufacturer’s protocol and eluted with 10 mM reduced glutathione (G4251,
Millipore Sigma). To remove glutathione and concentrate proteins, the eluates were
spun using Amicon Ultra-15 Centrifugal Filter Unit (UFC901096, Millipore Sigma)
with dialysis buffer (25 mM Tris-HCl (pH 8.0), 100 mM NaCl).
Real-time RT–PCR analyses and p53 PCR array. Total RNA was extracted from
cells using the RNeasy Plus Mini Kit (74136, Qiagen), and the concentration was
measured using the NanoDrop ND-1000 system (Thermo Scientiﬁc). Reverse
transcription was performed using the First Strand cDNA Synthesis Kit
(NP100042, Origen) with 0.5 µg total RNA. Real-time PCR was performed with
Maxima SYBR Green qPCR Master Mix (K0253, Thermo Scientiﬁc) using the
Roche LightCycler 480. The primers used for real-time PCR are listed as follows: q-
GAPDH-F: GGAGCGAGATCCCTCCAAAAT, q-GAPDH-R: GGCTGTTGTCA
TACTTCTCATGG, q-CDKN1A-F: TACCCTTGTGCCTCGCTCAG, q-CDKN
1A-R: GAGAAGATCAGCCGGCGTTT, q-MDM2-F: GAATCTACAGGGACGC
CATC, q-MDM2-R: TCCTGATCCAACCAATCACC, q-BAX-F: CCGCCGTGGA
CACAGAC, q-BAX-R: CAGAAAACATGTCAGCTGCCA, q-PUMA-F: GGGCC
CAGACTGTGAATCCT, q-PUMA-R: ACTTGCTCTCTCTAAACCTAT, q-
NOXA-F: GTGTGCTACTCAACTCAG, q-NOXA-R: ATTCCTCTCAATTA-
CAATGC, q-GADD45a-F: GAGAGCAGAAGACCGAAAGGA, q-GADD45a-R:
CAGTGATCGTGCGCTGACT, q-APAF1-F: AAAAGGGGATAGAACCAGAGG,
q-APAF1-R: TGCGGCACCTCAAGTCTTC, q-BAI1-F: GCAAACCAAGTTCT
GCAACAT, q-BAI1-R: CTCCAGCTCGACCACTCATT, q-BCL2A1-F: AGTGC-
TACAAAATGTTGCGTTC, q-BCL2A1-R: gGCAATTTGCTGTCGTAGAAGTT,
q-BTG2-F: GCGAGCAGAGGCTTAAGGT, q-BTG2-R: GGGAAACCAGTGGT
GTTTGTA, q-CDC25c-F: TCCCTGAAAGATCAAGAAGC, q-CDC25c-R: CC
TTGGAAAAATCACCAATC, q-FAS-F: GGGGTGGCTTTGTCTTCTTCTTTTG,
q-FAS-R: ACCTTGGTTTTCCTTTCTGTGCTTTCT, q-PIDD-F: TCTGACAC
GGTGGAGATGTTCG, q-PIDD-R: AGGTGCGAGTAGAAGACAAAGCAG, q-
RPRM-F: AGCAAACCTGTCGGAGTCAA, q-RPRM-R: CTCCCCGCATTC-
CAAGTAAG, q-TNFRSF10B-F: CTCTGAGACAGTGCTTCGATGACT and q-
TNFRSF10B-R: CCATGAGGCCCAACTTCCT. GAPDH was used as an internal
control. Data are shown as mean ± SEM for three independent experiments.
The p53 Signaling Pathway RT2 Proﬁler PCR Array (PAHS-027Z, Qiagen),
consisting of 84 genes related to p53-mediated signal transduction, was used to
proﬁle H1299-PBRM1-KO#1 cells transfected with p53 according to the
manufacturer’s instructions. Brieﬂy, H1299 and H1299-PBRM1-KO#1 cells were
transfected with vector or p53 for 24 h before RNA was extracted. The expression
of p53 was comparable by immunoblot detection. RNA was reverse transcribed
using the RT2 First Strand Kit (330404, Qiagen). The cDNA was mixed with RT2
SYBR Green qPCR Master Mix (330502, Qiagen), and equal aliquots of this
mixture (25 μl) were added to each well of the same PCR Array plate that contained
the predispensed gene-speciﬁc primer sets. Real-time PCR and data collection were
performed on the LightCycler 480 (Roche). Data were analyzed on http://www.
sabiosciences.com/pcrarraydataanalysis.php.
Chromatin immunoprecipitation (ChIP). ChIP assays were performed with the
Pierce Agarose ChIP Kit (26156, Thermo Scientiﬁc) according to the manu-
facturer’s instructions with minor revisions. In brief, samples were crosslinked with
1% paraformaldehyde and halted by 125 mM glycine. After washing twice with ice-
cold PBS, cells were harvested and suspended in Lysis Buffer 1 and incubated on ice
for 10 min. 1 × 107 nuclei were resuspended in 500 μl MNase Digestion Buffer
containing 6.25 U Micrococcal Nuclease and incubated at 37 °C for 15 min. After
the reaction was stopped, nuclei were pelleted by centrifugation and resuspended in
250 μl Lysis Buffer 2. Nuclei were sonicated at 10% amplitude for 10 s twice and
incubated on ice for 30 min. After centrifugation, 50 μl supernatant containing the
digested chromatin from 2 × 106 nuclei was diluted in 1× IP Dilution Buffer and
incubated with antibodies (normal rabbit IgG for control, 1 μg FL393+ 1 μg DO-1
for p53 or 2 μg Flag M2 for Flag-PBRM1) overnight at 4 °C. Twenty liters of ChIP
Grade Protein A/G Plus Agarose was added and incubated for 1 h at 4 °C. The
agarose resins were washed once with IP Wash Buffer 1, twice with IP Wash Buffer
2 and once with IP Wash Buffer 3. 150 μl 1× IP Elution Buffer was added to the
washed resin and incubated at 65 °C for 30 min with shaking. The eluate was
treated with Proteinase K and DNA was extracted with columns provided in the
kit. The resulting puriﬁed DNA was used in real-time PCR detection with the
primers listed as follows: qCHIP-p21-RE1-F: AGCAGGCTGTGGCTCTGATT,
qCHIP-p21-RE1-R: CAAAATAGCCACCAGCCTCTTCT, qCHIP-p21-TSS-F:
TATATCAGGGCCGCGCTG, qCHIP-p21-TSS-R: GGCTCCACAAGGAACTG
ACTTC, qCHIP-p21-intron1-F: AGTCACTCAGCCCTGGAGTCAA and qCHIP-
p21-intron1-R: GGAGAGTGAGTTTGCCCATGA.
Animal and mouse xenograft tumorigenesis assay. All animal experiments were
performed following the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health and protocol 01462–935A approved by the Thomas
Fig. 5 K382Ac recognition by PBRM1 is critical for p53 function in ccRCC cells. a, b ACHN (a) or Caki-1 (b) control and PBRM1 shRNA knockdown cells
were treated with 50 μM etoposide for the indicated time points. Lysates were analyzed by immunoblots. c RCC4 cells with or without p53 KO were
transfected with vector or Flag-PBRM1 at the indicated amounts. Lysates were analyzed by immunoblots. d ACHN control and PBRM1 shRNA #1
knockdown cells were treated with 10 μM Nutlin-3a for the indicated time points. Lysates were analyzed by immunoblots. e RCC4 cells stably expressing
GFP, wild-type PBRM1, or BD4* mutant PBRM1 were treated with 100 μM etoposide for the indicated time points. Lysates were analyzed by immunoblots.
f RCC4 cells stably expressing GFP, wild-type or indicated PBRM1 mutants were treated with 100 μM etoposide for the indicated times, and lysates were
examined via immunoblots. g, h RCC4 cells stably expressing GFP, wild-type or BD4* mutant PBRM1 were treated with 100 μM etoposide for 24 h. Cells
were harvested for RT-qPCR (g) or ChIP followed by qPCR (h). Data are shown as mean ± SEM. p-values were calculated using the paired two-tailed
Student’s t-test. i, j ACHN control and PBRM1 shRNA knockdown cells were treated with vehicle or 50 μM etoposide for cell cycle analysis. Representative
data is shown in i. Quantiﬁcation of cell cycle phase is shown in j. Source data are provided as a Source Data ﬁle.
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Jefferson University Animal Care and Use Committee. 1 × 107 cells in 100 μl PBS
were injected into one side of the dorsal ﬂank of 4–6-week-old male Nu/J nude
mice (Charles River). The same number of cells of another cell line were injected
into the other ﬂank of the same mouse. Ten mice were analyzed in this manner per
experiment. Tumor growth was monitored regularly for up to 14 days. The mice
were sacriﬁced and tumors were dissected and weighed. Signiﬁcance differences in
tumor weight were determined by the two-tailed Student’s paired t-test.
Tissue microarray (TMA) and IHC. 160 patients diagnosed with ccRCC were
selected from Fox Chase cancer Center with the protocol approved by Fox Chase
Ren-01-PBRM1-KOa
c d e
f g h
b SLR24
GFP
IB: p21
IB: PUMA
IB: MDM2
IB: K382Ac
IB: p53
IB: PBRM1
IB: Vinculin
IB: p21
IB: PUMA
IB: MDM2
IB: K382Ac
IB: p53
IB: PBRM1
IB: Vinculin
IHC
PBRM1
GFP
GFP PBRM1 (WT)
Ren-01-PBRM1-KO
PBRM1-WT
PBRM1-WT
PBRM1-BD4*
p21
PBRM1-WT
PBRM1-BD4*
50 μM etoposide (h)
GFP
PBRM1-WT
PBRM1-BD4*
50 μM etoposide (h)
+
–
–
0
–
+
–
0
–
–
+
0
+
–
–
8
–
+
–
8
–
–
+
8
+
–
–
16
–
+
–
16
–
–
+
16
+
–
–
24
–
+
–
24
–
–
+
24
1 4.3 0.9 4 13.1 3.3 3.4 13.2 3.7 2.2 8.5 3.5
1 2.2 1.4 3.3 7.5 2.8 4.1 9.9 4.1 2.6 7.6 4.4
1 1.3 0.6 1.6 2.7 1.5 0.9 1.5 0.9 0.8 1.3 1.1
1 2 3 4 5 6 7 8 9 10 11 12
+
–
–
0
–
+
–
0
–
–
+
0
+
–
–
8
–
+
–
8
–
–
+
8
+
–
–
16
–
+
–
16
–
–
+
16
+
–
–
24
–
+
–
24
–
–
+
24
20 20
25
100
50
50
250
100
25
100
50
50
250
100
1 2 3 4 5 6 7 8
3
2.0
1.5
1.0
0.5
0.0
p = 0.0213
p = 0.0034
2
Tu
m
o
r 
w
e
ig
ht
 (g
)
Tu
m
o
r 
w
e
ig
ht
 (g
)
1
0
GF
P
PB
RM
1 (W
T)
PB
RM
1 (W
T)
PB
RM
1-B
D4
*
9 10 11 12
1 1 0.9 2.2 3.4 2.7 3 4.2 2.8 3.4 6.4 3.8
1 1.1 0.7 1.3 2.1 1.4 1.2 1.4 1.3 1.7 2.2 1.4
1 1.4 0.7 1.6 2.4 1.6 1.9 2.3 1.6 1.5 1.6 1
IHC
PBRM1 p21
PBRM1 (WT) PBRM1-BD4*
Ren-01-PBRM1-KO
Fig. 6 Mutation of BD4 abolishes the tumor suppressive function of PBRM1. a, b GFP, wild-type or BD4* mutant PBRM1 were stably expressed in Ren-01
PBRM1 KO cells (combination of three clones) (a) or PBRM1-null SLR24 cells (b). Cells were treated with 50 μM etoposide for the indicated times, and
lysates were analyzed via immunoblots with indicated antibodies. The band intensity of indicated protein was measured with Bio-rad Image Lab 4.1, and the
relative ratios were calculated over the signal intensity of Vinculin in the corresponding lanes. c–e. Nude mice xenograft analyses were performed with Ren-
01 PBRM1 KO cells expressing GFP (left ﬂank) or PBRM1 (right ﬂank). Representative photographs of a mouse (c, top) and tumors (c, bottom). Tumors
were excised and weighed, and data are presented as mean ± SEM (d). p-values were calculated using the paired two-tailed Student’s t-test. Tumors were
stained for PBRM1 and p21 expression via IHC (e). Scale bar: 200 μm. f–h Nude mice xenograft analyses were performed with Ren-01 PBRM1 KO cells
expressing wild-type PBRM1 (left ﬂank) or the BD4* mutant PBRM1 (right ﬂank). Tumors were excised and weighed, and data are presented as mean ±
SEM (g). p-values were calculated using the paired two-tailed Student’s t-test. Representative photographs of a mouse (f, top) and tumors (f, bottom).
Tumors were stained for PBRM1 and p21 expression via IHC analysis (h). Scale bar: 200 μm. Source data are provided as a Source Data ﬁle.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13608-1
12 NATURE COMMUNICATIONS |         (2019) 10:5800 | https://doi.org/10.1038/s41467-019-13608-1 | www.nature.com/naturecommunications
Cancer Center IACUC committee (IRB#13–810). Forty cases from each of the four
tumor stages (Stage I–IV) were randomly picked. Four foci from each tumor were
used to generate TMA. Mice tumors were ﬁxed with 200 ml 4% paraformaldehyde
with stirring at room temperature overnight. Human ccRCC tumor TMA KD806
was purchased from US Biomax Inc.
Four micrometers of parafﬁn slides were deparafﬁnized in Shandon Varistain
Gemini ES Autostainer. Antigen retrieval was performed with DAKO PTLink
using Citrate Buffer (pH 6.0) at 98˚C for 20 min. Primary immunostaining was
performed using antibodies against p21 (Cell-Signaling, cat#:#2947, 1:25), anti-p53
K382Ac antibody (GTX62061, 1:250), and PBRM1 (Bethyl labs, Cat# A301–591A,
1:50), Antibodies were incubated at room temperature for 30 min. Biotinylated
anti-Rabbit (Vector Laboratories, cat#: BA-1000) secondary antibody and ABC-
HRP complexes (Vector Laboratories, Cat#: PK6100) were applied following the
primary antibodies. Each reagent was incubated for 30 min at room temperature.
Three TBST washes were performed between steps. The signals were visualized
with DAB substrate (DAKO, Cat#: K3468). Slides were then washed with DI water
and processed with Hematoxylin counter stain, dehydrated and cleared in Shandon
Varistain Gemini ES Autostainer. Finally the slides were coverslipped with
Permount Mounting Medium.
Pathologist Dr. Wei Jiang performed the scoring of the stained foci. If greater
than 50% of tumor cells were considered positive in a focus a score of 2 is given, 1 if
<50% but greater than 5% of tumor cells were considered positive, and 0 if <5% of
tumor cells were stained positive. If one marker is scored as 0 in one focus, then
that whole tumor is deemed to have a score of 0 for that marker.
Statistical analysis and reproducibility. Individual in vitro experiments were
performed three times unless otherwise indicated. The signiﬁcance of three bio-
logical independent experimental data was determined by the two-tailed Student’s
paired t-test. P-value < 0.05 was considered signiﬁcant and the numbers are indi-
cated in the ﬁgures. Results are expressed as mean ± SEM. Categorical variables
were compared between groups of TMA using Fisher’s exact tests. No animals were
excluded from experiments. No statistical method was used to predetermine
sample size. Sample size was chosen on the basis of literature in the ﬁeld.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Human ccRCC TMA
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Fig. 7 PBRM1 loss and p21 loss positively correlate in human ccRCC tumors. a 160 ccRCC tumors (40 tumors per stage) were used to generate a tissue
microarray (TMA). Four foci from different regions of each tumor were selected. PBRM1 expression was analyzed and scored in our previous report47,48
(a, bottom). p21 expression was analyzed and scored in the tumors (a, top) by a blinded pathologist. Scale bar: 100 μm. b p-values of correlations between
PBRM1 loss and p21 loss in human ccRCC samples. c A model depicting how PBRM1 may regulate tumor growth in ccRCC through recognition of p53
K382Ac. Source data are provided as a Source Data ﬁle.
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Data availability
Statistics source data for graphical representations and statistical analyses in Figs. 1–7,
Supplementary Figs. 1–6 and Supplementary Table 1 are provided in PBRM1-p53-
SourceData ﬁle. All the other data supporting the ﬁndings of this study are available from
the corresponding author upon reasonable request.
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